Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.

[1]  A. Nicolini,et al.  Primary prophylaxis of variceal bleeding in cirrhotic patients: a cohort study. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  R. Groszmann,et al.  Portal hypertension and variceal bleeding—Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single‐topic conference , 2008, Hepatology.

[3]  A. Sanyal,et al.  Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. , 2007, The American journal of gastroenterology.

[4]  Ramon Planas,et al.  Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. , 2007, Gastroenterology.

[5]  R. Koretz,et al.  Hepatology may have problems with putative surrogate outcome measures. , 2007, Journal of hepatology.

[6]  J. Bosch,et al.  Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis , 2006, The American Journal of Gastroenterology.

[7]  Ziv J Haskal,et al.  The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension , 2005, Hepatology.

[8]  J. Miñana,et al.  Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. , 2004, Journal of hepatology.

[9]  R. Groszmann,et al.  The hepatic venous pressure gradient: Anything worth doing should be done right , 2004, Hepatology.

[10]  J. Calleja,et al.  Propranolol plus placebo versus propranolol plus isosorbide‐5‐mononitrate in the prevention of a first variceal bleed: A double‐blind RCT , 2003, Hepatology.

[11]  G. D’Amico,et al.  Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of the first bleeding in cirrhosis. A double-blind placebo-controlled randomised trial , 2002 .

[12]  R. Groszmann,et al.  Propranolol for the prevention of first esophageal variceal hemorrhage: A lifetime commitment? , 2001, Hepatology.

[13]  T M Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.

[14]  A. Gatta,et al.  The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis , 2000, Hepatology.

[15]  M. Bolognesi,et al.  Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis. , 1999, European journal of gastroenterology & hepatology.

[16]  R. Makuch,et al.  Portal hypertension and variceal bleeding: An AASLD single topic symposium , 1998, Hepatology.

[17]  A. Burroughs,et al.  Hepatic venous pressure measurement: An old test as a new prognostic marker in cirrhosis? , 1997, Hepatology.

[18]  P. Amodio,et al.  Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis , 1996, The Lancet.

[19]  R. Groszmann,et al.  Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. , 1996, Gastroenterology.

[20]  G. D’Amico,et al.  The treatment of portal hypertension: A meta‐analytic review , 1995, Hepatology.

[21]  P. Angeli,et al.  Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. , 1992, Gastroenterology.

[22]  J. Korula.  Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. , 1991, Gastroenterology.

[23]  U. Elkayam.  Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. , 1991, Annals of internal medicine.

[24]  P. Angeli,et al.  Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. , 1989, Journal of hepatology.

[25]  N Tygstrup,et al.  Changes of laboratory variables with time in cirrhosis: Prognostic and therapeutic significance , 1985, Hepatology.

[26]  S. Kitano,et al.  Prediction of variceal hemorrhage by esophageal endoscopy. , 1981, Gastrointestinal endoscopy.

[27]  N. Tygstrup,et al.  Enzymatic elimination of substrates flowing through the intact liver. , 1976, Journal of theoretical biology.

[28]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[29]  L. Caregaro,et al.  Long-term effect of nadolol on quantitative liver function tests in patients with cirrhosis , 2004, European Journal of Clinical Pharmacology.